• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Adagene Inc.

    5/22/25 5:05:23 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email
    6-K 1 tm2515682d1_6k.htm FORM 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-
    16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of May 2025

     

    Commission File Number: 001-39997

     

     

     

    Adagene Inc.

     

     

     

    4F, Building C14, No. 218

    Xinghu Street, Suzhou Industrial Park

    Suzhou, Jiangsu Province, 215123

    People’s Republic of China

    +86-512-8777-3632

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x   Form 40-F ¨

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Adagene Inc.
       
      By: /s/ Peter Luo
      Name: Peter Luo
      Title: Chief Executive Officer
       
    Date: May 22, 2025  

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit   Description
         
    99.1   Press release titled “Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.”

     

     

     

    Get the next $ADAG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    8/6/2025$7.00Outperform
    Leerink Partners
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Adagene with a new price target

    Leerink Partners initiated coverage of Adagene with a rating of Outperform and set a new price target of $7.00

    8/6/25 7:24:59 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene downgraded by Morgan Stanley

    Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

    1/31/25 8:29:36 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley reiterated coverage on Adagene with a new price target

    Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously

    2/1/22 9:41:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ADAG
    SEC Filings

    View All

    Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

    SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene's SAFEbody technology platform to generate a masked monoclonal antibody from the company's pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to receive development and commercialization milestones and royalties on net sales of products developed around this target. Peter Luo, Ph.D., Chief Executive Officer of Adagene said, "Our SAFEbody techn

    9/16/25 8:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

    SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year's CSCO Meeting, taking place September 10-14 in Jinan, China. Harnessing the Power of Masked CTLA-4 Blockade: Updated ADG126-P001 Phase 1b/2Results of ADG126 + Pembrolizumab in Advanced MSS CRC Presenter: Dr. Xu Ruihua, Professor and President of Sun Yat-sen University Cancer Center and Chairman of the Chinese Society of Clinical Oncology (CSCO)Date and Time: Thursday, September 11 at 14:45-15:

    9/5/25 9:55:13 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Adagene Inc.

    6-K - Adagene Inc. (0001818838) (Filer)

    8/12/25 4:06:01 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Adagene Inc.

    6-K - Adagene Inc. (0001818838) (Filer)

    7/15/25 7:00:59 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagene Inc.

    SCHEDULE 13G/A - Adagene Inc. (0001818838) (Subject)

    7/2/25 1:53:09 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adagene Inc.

    SC 13G/A - Adagene Inc. (0001818838) (Subject)

    11/7/24 4:32:13 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Adagene Inc. (Amendment)

    SC 13D/A - Adagene Inc. (0001818838) (Subject)

    3/1/24 4:30:20 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Adagene Inc. (Amendment)

    SC 13G/A - Adagene Inc. (0001818838) (Subject)

    2/9/24 8:35:54 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Leadership Updates

    Live Leadership Updates

    View All

    Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

    SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. "Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broad

    9/3/25 9:05:21 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

    - Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. "Adagene is currently breaking a toxicity barrier with their proprietary masking technology, delivering a checkpoint inhibitor selectively and conditionally to tumor cells. Their platform has broad potential for enhanced immunotherapy with effective regulatory T-cell depletion, in conjunction with monoclonal antibodies, bispecifics, T-cell engagers, and antibod

    4/28/25 8:00:00 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

    - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a

    3/7/24 4:01:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    Financials

    Live finance-specific insights

    View All

    Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

    – Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of

    8/30/22 5:25:00 PM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care